versameb in the news

29 May 2024 | Nature Biotechnology

Femtechs take on women’s health

An upsurge in biotechs focused on women’s health responds to a fresh understanding of female biology to develop new tools and treatments.
Versameb, in Basel, Switzerland, hopes to tackle the common condition, urinary incontinence, using mRNA. The company’s research builds on studies of insulin-like growth factor 1 (IGF-1), a signaling molecule that can regenerate the urethral sphincter in animal models.

Read more >

3 June 2022 | Genetic Engineering & Biotechnology News (GEN)

RNA Leaders Explore New Frontiers in mRNA-Based Medications

Versameb CEO Klaas Zuideveld spoke with Vivienne Raper from Genetic Engineering & Biotechnology News for her article that explores how Versameb and other companies are harnessing the therapeutic potential of RNA to make medicines.

Read more >

6 April 2022 | Drug Target Review

The promise of mRNA therapeutics in producing the first regenerative treatment for SUI

In an exclusive article, Dr Roger Dmochowski, Professor of Urology and Associate Surgeon in Chief for Vanderbilt University Medical Center and member of the Versameb Advisory Board, discusses the promise of potential new regenerative for Stress Urinary Incontinence.

Read more >

17 May 2021 | In Vivo Informa Pharma Intelligence

In Vivo’s 2021 Rising Leaders: Recognizing Talent Across The Life Sciences

Versameb CEO Klaas Zuideveld has been named as one of 30 people in In Vivo’s 2021 ‘Rising Leaders in the Life Sciences.

Read more >

17 May 2021 |  In Vivo Informa Pharma Intelligence

Versameb CEO Klaas Zuideveld Talks RNA Spotlight and Biotech Culture
An Interview With Klaas Zuideveld.

As part of In Vivo’s Rising Leaders series, Versameb CEO Klaas Zuideveld discusses the next-generation RNA company’s technology and target indications. He also shares more about his career journey, lessons learned, and gives insight into the contrasting business cultures within big pharma and biotech.

Read more (Subscription only) >